Neurochem's eprodisate (KIACTA(TM)) PDUFA date extended three months by FDA



    ECUBLENS, Switzerland, April 11 /CNW Telbec/ - Neurochem (International)
Limited (Neurochem), a wholly owned subsidiary of Neurochem Inc.
(NASDAQ:   NRMX; TSX: NRM), announces that it received notification from the
United States Food and Drug Administration (FDA) that the action date for
FDA's review of the New Drug Application (NDA) for eprodisate (KIACTA(TM)) for
the treatment of Amyloid A (AA) amyloidosis, has been extended to July 16,
2007. Previously, the action date under the Prescription Drug User Fee Act
(PDUFA) for the eprodisate (KIACTA(TM)) NDA was April 16, 2007.
    The FDA is extending the PDUFA goal date by three months to provide time
for a full review of an amendment to the eprodisate (KIACTA(TM)) NDA submitted
by Neurochem Inc. in February 2007. This additional submission is considered
by the FDA to be a major amendment to the NDA, allowing an extension of the
action date.

    About eprodisate (KIACTA(TM))

    Eprodisate (KIACTA(TM)) was investigated in a landmark international,
randomized, double-blind, placebo-controlled, and parallel-designed clinical
trial in which 183 AA amyloidosis patients were enrolled at 27 sites around
the world (Eprodisate for AA Amyloidosis Trial, EFAAT). Patients who completed
the clinical trial were eligible for enrollment in an ongoing open-label
extension study, some of whom have now been receiving eprodisate (KIACTA(TM))
for more than five years. Eprodisate (KIACTA(TM)) has received orphan drug
status in the United States, the European Union and in Switzerland.

    About Amyloid A (AA) Amyloidosis

    A progressive and fatal condition, AA amyloidosis occurs in a proportion
of patients with chronic inflammatory disorders, chronic infections and
inherited diseases such as Familial Mediterranean Fever. The kidney is the
organ most frequently affected and progression to dialysis/end-stage renal
disease is the most common clinical manifestation in this disease. Currently,
there is no approved therapy to treat AA amyloidosis and about half of all
patients diagnosed with the disease die within five years of diagnosis.
    The EFATT study was sponsored by Neurochem Inc.

    About Neurochem

    Neurochem Inc. is focused on the development and commercialization of
innovative therapeutics to address critical unmet medical needs. Eprodisate
(KIACTA(TM) - formerly FIBRILLEX(TM)) is currently being developed for the
treatment of Amyloid A (AA) amyloidosis, and is under regulatory review for
marketing approval by the United States Food and Drug Administration and
European Medicines Agency. Tramiprosate (ALZHEMED(TM)), for the treatment of
Alzheimer's disease, has completed a Phase III clinical trial in North America
and is currently in a Phase III clinical trial in Europe, while tramiprosate
(CEREBRIL(TM)), for the prevention of Hemorrhagic Stroke caused by Cerebral
Amyloid Angiopathy, has completed a Phase IIa clinical trial.

    To Contact Neurochem

    For additional information on Neurochem and its drug development
programs, please call the North American toll-free number 1 877 680-4500 or
visit our Web Site at www.neurochem.com.

    This news release contains forward-looking statements regarding
eprodisate (KIACTA(TM)), as well as regarding continuing and further
development efforts. These statements are based on the current analysis and
expectations of management. Drug development necessarily involves numerous
risks and uncertainties, which could cause actual results to differ materially
from this current analysis and these expectations. Analysis regarding the
results of clinical trials may not provide definitive results regarding
safety, tolerability or therapeutic benefits. There is no certainty that
regulators will ultimately approve eprodisate (KIACTA(TM)) for sale to the
public. Risks and uncertainties may include: failure to demonstrate the
safety, tolerability and efficacy of our product, that actual results may vary
once the final and quality-controlled verification of data and analyses has
been completed, the expense and uncertainty of obtaining regulatory approval,
including from the FDA, and the possibility of having to conduct additional
clinical trials. Further, even if regulatory approval is obtained, therapeutic
products are generally subject to: stringent on-going governmental regulation,
challenges in gaining market acceptance, and competition. Neither Neurochem
Inc., nor Neurochem (International) Limited undertake any obligation to
publicly update any forward-looking statements, whether as a result of new
information, future events, or otherwise. Please see Neurochem Inc.'s Annual
Information Form for further risk factors that might affect Neurochem Inc.,
Neurochem (International) Limited and their respective businesses.




For further information:

For further information: please contact: Lise Hébert, PhD, Vice
President, Corporate Communications, (450) 680-4572, lhebert@neurochem.com


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890